Preparing synthetic Aβ in different aggregation states
- PMID: 20967580
- PMCID: PMC3752843
- DOI: 10.1007/978-1-60761-744-0_2
Preparing synthetic Aβ in different aggregation states
Abstract
This chapter outlines protocols that produce homogenous preparations of oligomeric and fibrillar amyloid-β peptide (Aβ). While there are several isoforms of this peptide, the 42 amino acid form is the focus because of its genetic and pathological link to Alzheimer's disease (AD). Past decades of AD research highlight the dependence of Aβ42 function on its structural assembly state. Biochemical, cellular and in vivo studies of Aβ42 usually begin with purified peptide obtained by chemical synthesis or recombinant expression. The initial steps to solubilize and prepare these purified dry peptide stocks are critical to controlling the structural assembly of Aβ. To develop homogenous Aβ42 assemblies, we initially monomerize the peptide, erasing any "structural history" that could seed aggregation, by using a strong solvent. It is this starting material that has allowed us to define and optimize conditions that consistently produce homogenous solutions of soluble oligomeric and fibrillar Aβ42 assemblies. These preparations have been developed and characterized by using atomic force microscopy (AFM) to identify the structurally discrete species formed by Aβ42 under specific solution conditions. These preparations have been used extensively to demonstrate a variety of functional differences between oligomeric and fibrillar Aβ42. We also present a protocol for fluorescently labeling oligomeric Aβ42 that does not affect structure, as measured by AFM, or function, as measured by a cellular uptake assay. These reagents are critical experimental tools that allow for defining specific structure/function connections.
Figures
Similar articles
-
Dynamics of Inter-Molecular Interactions Between Single Aβ42 Oligomeric and Aggregate Species by High-Speed Atomic Force Microscopy.J Mol Biol. 2019 Jul 12;431(15):2687-2699. doi: 10.1016/j.jmb.2019.04.044. Epub 2019 May 7. J Mol Biol. 2019. PMID: 31075274
-
The coexistence of an equal amount of Alzheimer's amyloid-β 40 and 42 forms structurally stable and toxic oligomers through a distinct pathway.FEBS J. 2014 Jun;281(11):2674-87. doi: 10.1111/febs.12813. Epub 2014 May 6. FEBS J. 2014. PMID: 24720730
-
Understanding amyloid fibril nucleation and aβ oligomer/drug interactions from computer simulations.Acc Chem Res. 2014 Feb 18;47(2):603-11. doi: 10.1021/ar4002075. Epub 2013 Dec 24. Acc Chem Res. 2014. PMID: 24368046 Review.
-
Preparation of fluorescently-labeled amyloid-beta peptide assemblies: the effect of fluorophore conjugation on structure and function.J Mol Recognit. 2009 Sep-Oct;22(5):403-13. doi: 10.1002/jmr.948. J Mol Recognit. 2009. PMID: 19343729 Free PMC article.
-
Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease.Neurol Res. 2005 Dec;27(8):869-81. doi: 10.1179/016164105X49436. Neurol Res. 2005. PMID: 16354549 Review.
Cited by
-
Edaravone Dexborneol mitigates pathology in animal and cell culture models of Alzheimer's disease by inhibiting neuroinflammation and neuronal necroptosis.Cell Biosci. 2024 Apr 27;14(1):55. doi: 10.1186/s13578-024-01230-8. Cell Biosci. 2024. PMID: 38678262 Free PMC article.
-
APOE4/4 is linked to damaging lipid droplets in Alzheimer's disease microglia.Nature. 2024 Apr;628(8006):154-161. doi: 10.1038/s41586-024-07185-7. Epub 2024 Mar 13. Nature. 2024. PMID: 38480892 Free PMC article.
-
Disease-Associated Neurotoxic Astrocyte Markers in Alzheimer Disease Based on Integrative Single-Nucleus RNA Sequencing.Cell Mol Neurobiol. 2024 Feb 12;44(1):20. doi: 10.1007/s10571-024-01453-w. Cell Mol Neurobiol. 2024. PMID: 38345650 Free PMC article.
-
Secondary Modification of S100B Influences Anti Amyloid-β Aggregation Activity and Alzheimer's Disease Pathology.Int J Mol Sci. 2024 Feb 1;25(3):1787. doi: 10.3390/ijms25031787. Int J Mol Sci. 2024. PMID: 38339064 Free PMC article.
-
N1-methylation of adenosine (m1A) in ND5 mRNA leads to complex I dysfunction in Alzheimer's disease.Mol Psychiatry. 2024 May;29(5):1427-1439. doi: 10.1038/s41380-024-02421-y. Epub 2024 Jan 29. Mol Psychiatry. 2024. PMID: 38287100 Free PMC article.
References
-
- Mastrangelo IA, Ahmed M, Sato T, Liu W, Wang C, Hough P, Smith SO. High-resolution atomic force microscopy of soluble Abeta42 oligomers. J Mol Biol. 2006;358:106–19. - PubMed
-
- Huang TH, Yang DS, Plaskos NP, Go S, Yip CM, Fraser PE, Chakrabartty A. Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide. J Mol Biol. 2000;297:73–87. - PubMed
-
- Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol. 1997;4:119–25. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous